ABSTRACT
The current research deals with formulation and evaluation of Benazepril hydrochloride transdermal films, by varying ratios of polymers Eudragit RL100, Eudragit RS100 by film casting technique. Preformulation studies were conducted to check the solubility, melting point and partition coefficient. The eleven formulations were analyzed for physicochemical parameters and drug dissolution potential of transdermal films. All the formulations are transparent with minimum weight variation and uniform thickness. The drug content uniformity of all the formulations vary between 96.84 ± 3.7% to 96.98 ± 1.6% indicate uniform drug distribution. The low water vapour transmission values indicate good water vapour permeation. The folding endurance is between 246 ± 4.60 to 315 ± 4.13 indicates that the transdermal films can withstand rupture. In vitro drug dissolution study indicates maximum amount of drug 96.8% (F2) released in 24 h when compared with marketed formulation 84.81%. The release order follows Fickian diffusion. The formulation F2 was optimized based on drug flux, permeability coefficient and enhancement ratio.
ABSTRACT
Objective: The objective of this study was to develop and validate a novel ion-pair liquid chromatography method, in order to separate and assay of amlodipine/benazepril combination in capsules. This method was a fast, practical and additional choice in quality control laboratories. Methods: The chromatographic conditions comprised of a classical C18-type stationary phase (250 × 4.6 mm, 5μ), with a mobile phase consisting of: 45% of 10-3 M of cetrimide and 55% acetonitrile. The flow rate was 1 ml/min; the detection wavelength was at 242 nm, under ambient temperature. Results: The method was validated for linearity with correlation coefficients very close to one, the accuracy with mean recovery values between 95.0-105.0%, precision with relative standard deviations of the calculated concentrations less than 5.0% and specificity in the presence of degradation products and excipients. Conclusion: The results presented in this paper showed that the developed method was fast and applicable, for the separation and determination of amlodipine/benazepril combination in capsules.
ABSTRACT
Objective: To discuss the diagnosis and treatment process of abnormally elevated blood pressure in the patient treated with rifampicin and antihypertensive drugs, to analyze the interaction between rifampicin and antihypertensive drugs, and to improve the clinicians' understanding of the administration in the patients. Methods: The clinical materials of a patient treated with rifampicin and antihypertensive drugs were collected, and the relationship between the blood pressure change and drug was analyzed. The changes of concentrations of dihydropyridine-based calcium antagonists after administration of rifampin were observed and the relative literatures were reviewed. Results: A 58-year-old man with coughing and coughing for 1 month was admitted to hospital. The patient was definitely diagnosed as tuberculosis and hypertension before admission; the patient was treated with rifampicin, isoniazid, ethambutol, pyrazinamide, and felodipine together. The original treatment plan was continued and the blood pressure of the patient was monitored. On the 9th day of anti-tuberculosis treatment, the patient developed dizziness, chest tightness, and severe fluctuations in blood pressure. Then rifampicin was stopped and antihypertensive drugs were adjusted. At the beginning of blood pressure fluctuation of the patient, the combination of angiotensin-converting enzyme inhibitors and the increasing dose of dihydropyridine-based calcium antagonists did not control the blood pressure. The blood pressure began to decrease significantly at 36 h after rifampin was stopped. On the 18th day of anti-tuberculosis treatment, the original antihypertensive plan was restored and the blood pressure remained stable. Conclusion: Rifampicin can sometimes significantly reduce the effect iveness of antihypertensive drugs (such as dihydropyridine calcium antagonists), and the clinicians should pay attention to it.
ABSTRACT
Objective@#To study the effect of benazepril on the expression of nuclear factor E2 related factor 2 (Nrf2), nicotinamide adenine dinucleotide phosphate oxidase 4 (NOX4) and reactive oxygen species (ROS) concentration in rats with hepatic fibrosis and to explore the possible antifibrotic mechanism of benazepril.@*Methods@#Twenty-two healthy male Sprague-Dawley rats were randomly divided into 3 groups: control group (6 rats), model group (8 rats) and benazepril treatment group (8 rats). Two rats died during modeling and treatment in the model group and the benazepril treatment group, and a model of hepatic fibrosis induced by carbon tetrachloride (CCL4) was established. The rats in benazepril group were given benazepril for 8 weeks by gastric gavage. The assessment of liver tissue damage in each group was measured using conventional hematoxylin-eosin and Masson staining. The mRNA level of Nrf2, NOX4 in liver tissue was detected by RT-PCR, and serum ROS concentration was determined by colorimetry. All data were expressed in mean ± standard deviations, and were analyzed using SPSS21.0 statistical software. The data were compared using one-way analysis of variance, and the LSD-t method was used for pairwise comparison between the two groups. The correlation analysis was performed by Spearman’s correlation analysis.@*Results@#In the liver of the model group, with the aggravation of liver fibrosis the expression of Nrf2mRNA, NOX4 mRNA and ROS concentration were higher than control group [(4.01 ± 3.40), (31.78 ± 3.96), (1.82 ± 0.46) μg/ ml vs. (0.12 ± 0.11), (2.03 ± 0.31), (1.56±0.84) μg/ml, P < 0.05]. After benazepril treatment, NOX4 mRNA expression and ROS concentration were decreased than the model group [(15.93 ± 5.01), (0.78 ± 0.44) μg/ml vs. (31.78 ± 3.96), (1.82 ± 0.46) μg /ml, P < 0.05], while Nrf2 mRNA expression was higher than the model group [(6.69 ± 4.86) vs. (4.01 ± 3.40), P < 0.05]. There was a positive correlation between Nrf2 and NOX4, Nrf2 and ROS, and NOX4 and ROS (r = 0.616, 0.411, 0.802, P < 0.05).@*Conclusion@#Benazepril may exert an anti-hepatic fibrosis effect by activating Nrf2 expression, or may inhibit the ROS-mediated oxidative stress in response to NOX4.
ABSTRACT
To explore influence of bisoprolol combined benazepril on ECG and left ventricular diastolic function in hypertensive patients with acute heart failure (AHF).Methods :A total of 124 hypertensive patients with AHF were randomly and equally divided into routine treatment group and combined treatment group (received biso‐prolol combined benazepril based on routine treatment ) ,both groups were treated for two months .Therapeutic effect ,ECG indexes ,left ventricular diastolic function indexes ,levels of heart failure and myocardial injury markers etc .before and after treatment were compared between two groups .Results : After two‐month treatment ,total ef‐fective rate of combined treatment group was significantly higher than that of routine treatment group (96. 77% vs. 82. 26%, P＝0.008) ;compared with routine treatment group ,there were significant reductions in QRS wave dura‐tion [ (103. 87 ± 9.70) ms vs.(94.12 ± 8. 93) ms] ,QTc duration [ (432.37 ± 33. 24) msvs .(418.96 ± 29. 64) ms] , plane QRS‐T angle [ (59.75 ± 26. 61)°vs.(48.19 ± 22.30)°] ,mitral annulus late diastolic peak flow velocity (Am) [ (12.84 ± 3.40) cm／svs .(11. 39 ± 3. 11) cm／s] ,plasma levels of N terminal pro brain natriuretic peptide [ (1. 20 ± 0.58) μg／L vs .(0. 75 ± 0.47) μg／L] ,carbohydrate antigen 125 [ (19.10 ± 9.24) U／ml vs.(13.93 ± 7.85) U／ml] ,galectin‐3 [ (4.72 ± 2. 25) μg／L vs .(3.28 ± 1. 65) μg／L] ,cardiac troponin I [ (1.93 ± 0. 97) μg／L vs.(1. 46 ± 0. 85) μg／L] ,and significant rise in mitral early／late diastolic peak flow velocity (E／A) [(1. 18 ± 0.30) vs.(1. 31 ± 0. 28)] and mitral annulus early diastolic peak flow velocity (Em) [ (12.90 ± 3. 76) cm／svs.(14. 49 ± 3.25) cm／s] in combined treatment group , P＜0. 05 or ＜0.01. There was no significant difference in incidence rates of ad‐verse reactions between two groups , P＞0.05 all.Conclusion :Bisoprolol combined benazepril possesses significant therapeutic effect on hypertensive patients with AHF ,and its improving effect on ECG indexes and left ventricular diastolic function is significant .
ABSTRACT
OBJECTIVE: To observe the improvement effects of angiotensin converting enzyme inhibitor (ACEI) fosinopril, perindopril and benazepril on ventricular remodeling in patients with acute myocardial infarction (AMI), and to evaluate its safety. METHODS: A total of 96 AMI patients selected from our hospital during Jan. 2014-Oct. 2016 were divided into group A, B, C according to random number table, with 32 cases in each group. All patients received symptomatic treatment, underwent percutaneous coronary intervention, and then given ACEI after blood vessels recanalization and keeping blood pressure stable. Group A was given Fosinopril sodium tablets 10 mg, qd; group B was given Perindopril tert-butylamine tablets 4 mg, qd; group C was given Benazepril hydrochloride tablets 10 mg, qd. All groups were treated for consecutive 6 months. Cardiac structure and function indexes (LVESD, LVEDD, IVSD, LVPWD, LVEF, CO), hemodynamic indexes (SBP, DBP, HR) and related lab indexes (FPG, TG, TC, HDL-C, LDL-C, AST, ALT, Scr, BUN) of 3 groups were observed before and after treatment. The occurrence of ADR was recorded. RESULTS: Before treatment, there was no statistical significance in cardiac structure and function indexes, hemodynamic indexes or related lab indexes among 3 groups (P＞0. 05). After treatment, the levels of LVESD, LVEDD, LVPWD, CO, HR, FPG, TG, TC and LDL-C in 3 groups were decreased significantly, while the levels of LVEF and SBP were increased significantly, with statistical significance (尸＜0. 05). There was no statistical significance in above indexes among 3 groups after treatment (P＞0. 05). After treatment, the level of Scr in group B was significantly increased and higher than group A and C, with statistical significance (P＜0. 05). There was no statistical significance in the levels of IVSD, DBP, HDL-C, AST, ALT or BUN among 3 groups before and after treatment as well as the level of Scr between group A and C (P＞ 0. 05). There was no statistical significance in the incidence of ADR among 3 groups(P＞0. 05). CONCLUSIONS: Fosinopril, perindopril and benazepril can significantly improve ventricular remodeling in AMI patients, narrowing the heart cavity, increasing systolic pressure, lowering heart rate, reducing the oxygen consumption of the ventricle, with similar effects. Perindopril may increase the level of Scr, so fosinopril and benazepril are safe and suitable for AMI patients with renal function disorder.
ABSTRACT
Objective :To study safety and effectiveness of vitamin D combined benazepril on patients with essential hyper-tension (EH) and positive urine microalbumin (UMA).Methods :A total of 92 EH patients with positive UMA were ran-domly divided into benazepril group (n＝44 , received benazepril 5md/d ,placebo 1 capsule/d) and combined treatment group (n＝48 , received vitamin D3 400mg/d and benazepril 5mg/d) ,both groups were treated for 12 weeks.Levels of mean arterial pressure (MAP) ,serum creatinine (SCr) and UMA were measured and compared between two groups before and after treatment .Results :Compared with before treatment ,there were significant reductions in levels of MAP and UMA in two groups after treatment , P＝0.001 all ;compared with benazepril group ,there were significant reductions in levels of MAP [ (108.45 ± 15.09) mmHg vs.(101.1 ± 15.02) mmHg] and UMA [ (52.35 ± 17.45) mg/L vs.(43.75 ± 13.29) mg/L] in combined treatment group ,P＜0.05 or ＜0.01.There was no significant difference in SCr level between two groups before and after treatment , P＞0.05 all.Conclusion : Compared with pure benazepril antihypertensive treat-ment ,vitamin D combined benazepril possesses better therapeutic effect on reducing UMA and antihypertensive effect .And it is safe without obvious damage on kidney function ,which is worth extending .
ABSTRACT
Objective To study the protective effect of the sodium selenite and benazepril on renal interstitial fibro-sis(RIF) in rat model of unilateral ureteral obstruction(UUO) and its mechanism. Methods The male SD of clean grade rats were randomly divided into sham-operation group,UUO group(UUO model was established by li-gating unilateral ureter), UUO+ sodium selenite group group(sodium selenite 0.2 mg/kg·d gavage), UUO+benazepril group(benazepril 10 mg/kg·d gavage),with 18 in each group.At day 7,14 and 21 after thetreatment, 6 rats selected randomly from each group were killed.The extent of RIF was evaluated by HE and Masson staining of the renal tissue. The expression of connective tissue growth factor(CTGF),transforming growth factor-β1(TGF-β1), alpha smooth muscle actin(α-SMA) andⅢ collagen(ColⅢ) were detected by immunohistochemical method.The protein expression of CTGF and TGF-β1 were detected by Western blot. Chemical colorimetric method was used to detecte the contents of supper oxide dismutase (SOD),malondialdehyde (MDA) and glutathione peroxidase (GSH-px) in renal cortex. Results The extent of RIF and the expression of CTGF,TGF-β1,α-SMA and ColⅢin renal cortex were significantly lower in sodium selenite group and benazepril group at day 7,14 and 21 after the op-eration compared with that in UUO group(P<0.05 or P<0.01). In sodium selenite group and benazepril group,the contents of SOD and GSH-px in renal cortex were higher significantly than those in UUO group at day 7,14 and 21 after the operation respectively(P<0.05),but the MDA in renal cortex was significantly decreased(P<0.05).There were no significant differences in the indexes between the two groups of sodium selenite and benazepril. The expres-sion of CTGF,TGF-β1,α-SMA,ColⅢand the extent of RIF were positively correlated to the level of MDA in UUO group(P<0.05,respectively),and negatively correlated to the level of SOD and GSH-Px(P<0.05,respectively). The expression of CTGF was positively correlated to the expression of α-SMA and ColⅢin UUO group(P<0.05).The expres-sion of CTGF,α-SMA and ColⅢwere positively correlated to RIF in UUO group(P<0.05).Conclusions Sodium sele-nite and benazepril can reduce the extent of RIF in rat model with unilateral ureteral obstruction.
ABSTRACT
Objective:To explore safety of benapril combined amlodipine on hypertension and its influence on levels of plasm total cholesterol (TC) and triglyceride (TG).Methods:A total of 180 hypertensive patients treated in our hospital were selected,randomly and equally divided into amlodipine group and combined treatment group (received amlodipine combined benapril therapy ),both groups were continuously treated for one month.Therapeutic outcome and incidence of adverse reactions were compared between two groups.Results:After treatment,compared with amlo-dipine group,there were significant reductions in systolic blood pressure [(146.3 ± 11.9) mmHg vs.(133.4 ± 15.1) mm-Hg],diastolic blood pressure [(90.5 ± 5.9) mmHg vs.(81.4 ± 6.1) mmHg],heart rate [(85.4 ± 10.8) beats/min vs.(74.5 ± 12.6) beats/min],levels of plasm TC [(5.17 ± 1.75) mmol vs.(3.52 ± 1.85) mmol] and TG[(1.64 ± 0.14) mmol vs.(1.32 ± 0.32) mmol] in combined treatment group,P＝0.001 all.Total incidence rate of adverse reactions of combined treatment group was significantly lower than that of amlodipine group (3.3% vs.15.6%,P＝0.005).Conclu-sion:Benapril combined amlodipine can significantly reduce heart rate,blood pressure and levels of plasm total cholesterol and triglyceride in hypertensive patients.It＇s safe and effective,which is worth extending.
ABSTRACT
A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan. The test group (n = 34) received Fortekor Plus twice daily. Two control groups received registered formulations of benazepril (Fortekor; Elanco Animal Health) and pimobendan (Vetmedin; Boehringer Ingelheim Vetmedica) with administration of Vetmedin twice daily and Fortekor twice (Control I, n = 14) or once (Control II, n = 19) daily. Diuretics were used in 22 dogs (32.8%). Global clinical scores decreased significantly from baseline in all groups; there were no significant differences between groups, and non-inferiority of Fortekor Plus compared to Control I, Control II, and combined Control I + II groups was demonstrated. There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events. Frequency of emesis was significantly (p = 0.0042) lower in the Fortekor Plus (8.8%) group than in the Control I + II (39.4%) group. In conclusion, Fortekor Plus had non-inferior efficacy and was associated with significantly less emesis compared to Fortekor and Vetmedin in dogs with CHF caused by MMVD.
Subject(s)
Animals , Dogs , Chemistry, Clinical , Diuretics , Estrogens, Conjugated (USP) , Heart Failure , Hematology , Japan , Masks , Mitral Valve , VomitingABSTRACT
OBJECTIVES@#Investigate the influence of benazepril and amlodipine on the expression of secretin (PZ) and somatostatin (SS) in spontaneously hypertensive rats (SHR).@*METHODS@#Forty-five SHRs (14 weeks old, male) were randomly assigned into 3 groups (=15):SHR group, Benazepril group (which was given benazepril 0.90 mg·kg·d) and Amlodipine group (SHRs were given amlodipine 0.45 mg· kg·d), taking WistarKyoto(WKY) as normal control (=15), meanwhile, rats in SHR group and WKY group were given the same volume of distilled water. After 8 weeks of intervention, the expression of protein and mRNA of PZ in duodenum and SS in sinuses ventriculi was detected by enzyme-linked immunoassay and RT-PCR.@*RESULTS@#After 8 weeks of intervention, compared with the WKY group, the expression of protein and mRNA of PZ in duodenum and SS in sinuses ventriculi was increased significantly in SHR group (<0. 05). Compared with SHR group, the expression of PZ in duodenum and SS in sinuses ventriculi was decreased significantly in Benazepril group and Amlodipine group (<0.05). Compared with Benazepril group, in Amlodipine group the expression of PZ mRNA in duodenum and SS mRNA in sinuses ventriculi was decreased more significantly (<0.05).@*CONCLUSIONS@#The regulation disorder of PZ in duodenum and SS in sinuses ventriculi exists in SHR. The antihypertensive effect of benazepril and amlodipine may be realized by regulating the expression of PZ and SS, while the regulation of amlodipine is more obvious than benazepril.
Subject(s)
Animals , Male , Rats , Amlodipine , Pharmacology , Antihypertensive Agents , Pharmacology , Benzazepines , Pharmacology , Blood Pressure , Hypertension , Drug Therapy , Random Allocation , Rats, Inbred SHR , Rats, Inbred WKY , Secretin , Metabolism , Somatostatin , MetabolismABSTRACT
Objective To investigate the clinical efficacy of benazepril combined with amlodipine in the treatment of essential hypertension.Methods From January 2016 to January 2017,90 patients with coronary heart disease in Taizhou Central Hospital were selected in the study,and they were randomly divided into three groups,with 30 cases in each group.The observation group(A group)was treated with benazepril combined with amlodipine,the control group (B group )was treated with benazepril,and the control group (C group)was treated with amlodipine. The clinical efficacy,blood pressure,blood lipid changes,blood glucose changes before and after treatment in the three groups were compared.Results The total effective rate of A group was 96.367%,which of B group was 66.67%, which of C group was 70.00%,and the clinical efficacy among the three groups had statistically significant difference (χ2＝11.96,P＜0.05).Before treatment,the systolic blood pressure(SBP)and diastolic blood pressure(DBP)of the three groups had no statistically significant differences(F＝0.98,0.85,all P＞0.05).After treatment,the SBP, DBP of the three groups were significantly lower than those before treatment(t＝5.68,7.21,3.52,3.16,3.64,3.16, all P＜0.05),the SBP and DBP of A group were significantly lower than those of B group and C group(F＝6.24, 3.27,all P＜0.05).After treatment,only the TC,TG,HDL－C levels of A group had statistically significant differ-ences compared with those before treatment(t＝5.29,6.28,2.31,all P＜0.05),and the TC,TG levels of A group were significantly lower than those of B group and C group(F＝3.18,2.86,all P＜0.05),while the HDL－C level of A group increased significantly compared with that of B group and C group(F＝3.78,P＜0.05 ).Before treatment, the FPG,FINS among the three groups had no statistically significant differences (F＝0.85,0.95,all P＞0.05 ). After treatment,only the FPG,FINS of A group had statistically significant differences compared with those before treatment(t＝5.14,3.65,all P＜0.05),and the FPG,FINS of A group were significantly lower than those of B group and C group(F＝5.27,2.86,all P＜0.05).The adverse reaction rate in A group was 6.67%,which in B group was 30.00%,which in group C was 26.67%,and there was no statistically significant difference among the three groups (χ2＝1.72,P＞0.05).Conclusion Benazepril combined with amlodipine in the treatment of essential hypertension is effective,safe,and has less adverse reactions.
ABSTRACT
Objective To investigate the efficacy and safety of atorvastatin combined with benazepril in the treatment of proteinuria in patients with IgA nephropathy ,so as to provide guidance for clinical medication .Methods Eighty patients with IgA nephropathy were selected ,and they were randomly divided into the observation group and control group according to random number table , with 40 patients in each group .The observation group was treated with atorvastatin combined with benazepril ,and the control group was treated with benazepril .The treatment effect of the two groups was compared.Results Before treatment,the 24h urinary protein,mean arterial pressure,serum creat-inine,blood urea nitrogen,and blood potassium between the two groups had no statistically significant differences (t=0.125,1.273,0.321,0.207,0.719,all P>0.05).After treatment,the 24h urine protein and mean arterial blood pressure in the two groups were lower than those before treatment , and the differences were statistically significant (t=2.735,6.145,3.434,4.501,all P<0.05),which in the observation group were lower than those in the control group,the differences were statistically significant (t=3.121,2.170,all P<0.05).The changes of serum creatinine, blood urea nitrogen and serum potassium in the two groups had no statistically significant differences (all P>0.05) .Conclusion Atorvastatin combined with benazepril in the treatment of IgA nephropathy can significantly decrease urinary protein level,without the adverse reactions of increased urea nitrogen ,creatinine and hyperkalemia ,which is worthy of popularization and application .
ABSTRACT
Objective:To explore therapeutic effect of spironolactone combined benazepril on patients with acute ante-rior myocardial infarction(AAMI)and its influence on left ventricular remodeling.Methods:A total of 100 AAMI patients treated in our hospital were regard as study object.According to therapeutic method,they were divided into benazepril group(n=50)and combined treatment group(n=50,received spironolactone combined benazepril),both groups were treated for six months.Therapeutic effect,left ventricular remodeling condition and incidence of adverse reactions were compared between two groups.Results:Compared with before treatment,after six-month treatment,there were significant rise in all indexes of heart rate variability(HRV)and left ventricular ejection fraction(LVEF),and significant reductions in left ventricular end-systolic dimension(LVESd)and left ventricular end-diastolic dimension(LVEDd)in two groups,P<0.05 or <0.01;compared with benazepril group after treatment,there were significant rise in all HRV indexes and LVEF[(52.45 ± 8.65)% vs.(57.85 ± 9.70)%],and significant reductions in LVESd[(36.25 ± 2.13)mm vs.(30.10 ± 2.06)mm]and LVEDd[(58.60 ± 6.41)mm vs.(51.29 ± 6.20)mm]in combined treatment group,P<0.01 all;there was no significant difference in total adverse reaction rate between two groups,P=1.000. Conclusion:Spironolactone combined benazepril can significantly improve HRV and heart function,inhibit left ventricular remodeling in patients with acute anterior myocardial infarction.
ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of benazepril combined with metoprolol in the treatment of elderly essential hypertension complicated with heart failure.METHODS:In retrospective analysis,100 elderly patients with essential hypertension complicated with heart failure were divided into control group (50 cases) and observation group (50 cases) according to drug plan.Based on routine treatment,control group was given Benazepril hydrochloride tablet 10 mg orally,once a day.Observation group was additionally given Metoprolol tartmte tablet with initial dose of 6.25 mg,twice a day,then increased 50-100 mg based on the improvement,twice a day,on the basis of control group.Relevant indicators were observed after 6 months of treatment.Clinical efficacies as well as SBP,DBP,brachial-ankle pulse wave velocity (baPWV),resting heart rate,LVEF,SV and the occurrence of ADR before and after treatment were observed in 2 groups.RESULTS:Total response rate of observation group (88.0％) was significantly higher than that of control group (62.0％),with statistical significance (P＜0.05).Before treatment,there was no statistical significance in SBP,DBP,baPWV,resting heart rate,LVEF and SV between 2 groups (P＞0.05).After treatment,SBP,DBP and baPWV of 2 groups were significantly lower than before,and the observation group was significantly lower than the control group;LVEF and SV of 2 groups were significantly higher than before,and the observation group was significantly higher than the control group;resting heart rate of observation group was significantly lower than before and that of control group,with statistical significance (P＜0.05),but there was no statistical significance in resting heart rate of control group before and after treatment (P＞0.05).No significant ADR was found in 2 groups during treatment.CONCLUSIONS:Based on routine treatment,benazepril combined with metoprolol show significant therapeutic efficacy for elderly hypertension complicated with heart rate,can improve cardiac function and blood pressure with good safety.
ABSTRACT
OBJECTIVE:To observe therapeutic efficacy and safety of benazepril combined with metoprolol in the treatment of elderly essential hypertension complicated with heart failure.METHODS:In retrospective analysis,100 elderly patients with essential hypertension complicated with heart failure were divided into control group (50 cases) and observation group (50 cases) according to drug plan.Based on routine treatment,control group was given Benazepril hydrochloride tablet 10 mg orally,once a day.Observation group was additionally given Metoprolol tartmte tablet with initial dose of 6.25 mg,twice a day,then increased 50-100 mg based on the improvement,twice a day,on the basis of control group.Relevant indicators were observed after 6 months of treatment.Clinical efficacies as well as SBP,DBP,brachial-ankle pulse wave velocity (baPWV),resting heart rate,LVEF,SV and the occurrence of ADR before and after treatment were observed in 2 groups.RESULTS:Total response rate of observation group (88.0％) was significantly higher than that of control group (62.0％),with statistical significance (P＜0.05).Before treatment,there was no statistical significance in SBP,DBP,baPWV,resting heart rate,LVEF and SV between 2 groups (P＞0.05).After treatment,SBP,DBP and baPWV of 2 groups were significantly lower than before,and the observation group was significantly lower than the control group;LVEF and SV of 2 groups were significantly higher than before,and the observation group was significantly higher than the control group;resting heart rate of observation group was significantly lower than before and that of control group,with statistical significance (P＜0.05),but there was no statistical significance in resting heart rate of control group before and after treatment (P＞0.05).No significant ADR was found in 2 groups during treatment.CONCLUSIONS:Based on routine treatment,benazepril combined with metoprolol show significant therapeutic efficacy for elderly hypertension complicated with heart rate,can improve cardiac function and blood pressure with good safety.
ABSTRACT
Objective:To observe influence of benazepril combined trimetazidine on blood levels of follistatin-like 1 (FSTL1)and platelet activating factor (PAF)and vascular endothelial function in patients with coronary heart dis-ease (CHD)complicated heart failure (HF).Methods:A total of 120 CHD patients with chronic heart failure were selected from our hospital.They were randomly and equally divided into benazepril group and combined treatment group (received benazepril combined trimetazidine therapy),both groups were treated for six months.Serum Blood levels of N-terminal pro brain natriuretic peptide (NT-proBNP),FSTL1 and PAF,endothelial progenitor cells (EPCs)count and fore brachial artery endothelium dependent diastolic-systolic function (FMD)before and after treatment were measured and compared between two groups.Results:Compared with before treatment,there were significant rise in left ventricular ejection fraction (LVEF),6min walking distance (6MWD),EPCs and FMD,and significant reductions in serum levels of NT-proBNP,FSTL1 and PAF after treatment in two groups,P <0.05 or <0.01;compared with benazepril group,there were significant rise in LVEF [(41.94±9.19)% vs.(46.15±10.04)%], 6MWD [(333.94±58.29)m vs.(383.14±77.84)m],EPCs [(0.059±0.029)pg/ml vs.(0.083±0.014)pg/ml]and FMD [(7.53±2.02)% vs.(8.24±1.42)%],and significant reductions in serum levels of NT-proBNP [(2.74±0.69) ng/ml vs.(2.05±0.34)ng/ml],FSTL1 [(5.38±1.29)ng/ml vs.(4.64±0.84)ng/ml]and PAF [(5.16±0.92)μg/ml vs.(4.20±1.05)μg/ml]in combined treatment group,P <0.05 or <0.01.Conclusion:Benazepril combined trimeta-zidine can effectively reduce blood levels of NT-proBNP,FSTL1 and PAF,and promote vascular endothelial function re-covery in patients with coronary heart disease complicated chronic heart failure.
ABSTRACT
Objective To analyze the effects of alprostadil combined with benazepril in the treatment of diabetes and the effect on blood glucose fluctuation.MethodsEighty cases with diabetes were randomly divided into the control group and the observation group with 40 cases in each group.The control group was treated with benazepril while the observation group was additionally treated with alprostadil.The treatment effects, the changes of blood glucose, blood lipids and renal function were compared between the two groups, and the incidence of adverse reactions was recorded.ResultsThe total effective rate in the observation group was higher than that in the control group (P<0.05).After treatment, the fasting plasma glucose (FPG), postprandial 2h plasma glucose (2hPG) and glycosylated hemoglobin (HbA1c) were reduced to the normal level but the volatility differences of FPG and 2hPG in the observation group were lower than those in the control group (P<0.05).After 4 weeks of treatment, the total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) decreased while high-density lipoprotein cholesterol (HDL-C) increased (P<0.05) but the differences between the two groups showed no statistical significance.After treatment, the improvement of renal function indexes in the observation group was better than that in the control group (P<0.05), and the incidence of adverse reactions showed no significant difference between the two groups.ConclusionThe application of alprostadil combined with benazepril in the treatment of diabetes can reduce blood glucose fluctuation, improve renal function, and reduce the risk of diabetic nephropathy.
ABSTRACT
Objective To investigate the clinical efficacy of psychological intervention combined with valsartan and Benner Pury in the treatment of congestive heart failure (CHF). Methods 100 patients with congestive heart failure treated in our hospital from January 2015 to October 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. Patients in the control group were treated with Benner Pury, the experimental group was given valsartan and Benner Pury combined treatment, and psychological intervention, pay attention to the psychological state of patients. The clinical indexes of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, the effective rate of treatment in the experimental group was 96%, and the effective rate of the control group was 82%. The effective rate of the patients in the control group was significantly lower than that in the experimental group, with statistical difference (P<0.05). The incidence of adverse reactions in the experimental group was 8%, and the fatality rate was 10%. The incidence of adverse reactions in the control group was 10%, and the fatality rate was 12%. There was no significant difference between the experimental group and the control group in the incidence of adverse reactions and mortality, and it was not statistically significant, and could be compared. Conclusion The clinical effect of psychological intervention combined with valsartan in the treatment of congestive heart failure, Benner Pury good, can improve the treatment efficiency to a certain extent, high safety, is further applied in clinical significance.
ABSTRACT
Objective To analyze the therapeutic values of valsartan combined with benazepril in the treatment of patients with congestive heart failure.Methods 102 cases of patients with congestive heart failure in Nine 0 Third Hospital were enrolled in the study.They were randomly divided into the control group and the observation group, with 51 cases in each group.Both groups were given cardiac diuretic, anti-infection and other basic treatment and the control group was given benazepril on the basis of basic treatment while the observation group was additionally given valsartan on the basis of treatment in the control group.The curative effects were compared and the changes of cardiac function indexes were detected before and after treatment between the two groups.Results The effective rate of treatment was 80.39% in the control group, which was lower than that in the observation group with 96.08% (P<0.05).After treatment, the observation group LVEF increased significantly, LVESd and LVEDd decreased significantly, and each index was significantly better than that of the control group (P<0.05).Conclusion Valsartan combined with benazepril in the treatment of congestive heart failure can effectively relieve the clinical symptoms and improve the cardiac function, therefore it is worthy of clinical promotion.